DISORDERS OF SEXUAL DIFFERENTIATION (DSD) Flashcards
‘____________________ ‘ is the term used when the external genitalia of a newborn can not be assigned a male or a female by the immediate caregivers.
Ambiguous genitalia
Several terms used in the past including ________,____________,_______________ etc are confusing and sometimes appear derogatory.
ESPE & LWPES in 2001 suggested the term “___________________” (DSDs)
ambiguous genitalia, intersex disorder, Hermaphrodites
Disorders of Sexual Differentiation
46, XX DSD: this accounts for about _____% of all DSD, Karyotype is 46,XX
Excessive exogenous virilization
•_____________ substances
•Excessive androgen production by the ________ during _________ (___________ or _____________)
Endogenous virilisation
•Congenital Adrenal Hyperplasia
With salt loss: (3B HSD2),______(CYP21) 90%
Without salt loss (_____): _______(CYP11B1)
•______________ deficiency
60
Androgenic substances; mother
pregnancy ; ovarian ; adrenal tumor
21-OH-ase ; (HTN)
11-OH-ase ; Aromatase
Aromatase is an enzyme that converts _________ into ___________, a key step in the biosynthesis of _________.
androgens
estrogens
estrogens
46, XY DSD: This accounts for about _____% of all DSD
•___________ testicles
•XY sex reversal
– ______ gene mutation (15 %)
– Duplication of the _____ arm of ____ chromosome:
•Double dose of DAX-1
•Anomalies of Sox 9 (________ defect),
-WT-1 or SF-1
Dysgenetic testicles
SRY gene mutation
short ; X
skeletal defect
46 XY DSD
Anomalies of testosterone or AMH synthesis
(a) Decrease in testosterone synthesis
–______ without virilization:
Deficiency in _______ (CYP11A)
Deficiency in _______ (3BHSD2)
Deficiency in ________/_________(CYP17)
–______________ in 17ßHSD (17BHSD3)
– (b) Decrease in AMH synthesis ( ______________________ Syndrome)
CAH; P450scc; 3ß HSD ; 17-OH-ase; 17-20 desmolase
Testicular Deficiency
Persistent Müllerian Duct
46 XY DSD
Anomalies of testosterone action
– Anomalies of _____ synthesis:
•_____________ deficiency
–__________________ syndrome: androgen receptor defects or of co-activators
Complete AIS: _________________ syndrome
Partial AIS: (______________)
– Resistance to ______________ disruptors
DHT ; 5Alpha Reductase
Androgen insensitivity; testicular feminization
Reifenstein ; AMH Endocrine
- Ovotesticular DSD:
Karyotype could be 46, XX (57 %), 46, XY/ 46, XX (30 %), 46, XY (13 %).
presence of _______________________________ ,
____________ is ambiguous,
one side could be _____________ structures and the other having ___________ structures and a feminine external genitalia.
Testicle and ovary or ovotestis
Internal genitalia; Mullerian ducts ; wolffian duct
- 45X, 46 XY DSD, Mixed gonadal dysgenesis.
presence of testicle and ovarian streak ___________________ internal genitalia and _____________ external genitalia
__________ syndrome stigmata in about 50%.
The Karyotype is __________/_________
mixture of male and female
ambiguous; Turner’s
46, XY/ 45, XO.
Clinical presentation
In the newborn:
– Absence of ___________
– _________ ± _________
– Apparent female with ————— , inguinal _________ , or slight __________ enlargement
– Apparent male with ____________ , ___________ or unusual ______ genitalia or gonads
palpable testis
Micropenis ± cryptorchidism
inguinal masses; hernias ; clitoral
cryptorchidism ; hypospadias ; small genitalia
Clinical presentation
During childhood and adolescence
– Girl with no _______ development or primary________
– Boys with ____________ and ___________
– Signs of __________ of an apparent girl at puberty
Breast; amenorrhea
gynecomastia ; testicular atrophy
virilization
Work up of a patient with DSD
Family history and Pregnancy
Clinical examination: careful and detailed external genitalia examination and correct measurement with a clinical picture
Internal genitalia: _________ and __________, eventually ___________ ± _________
__________, FISH, molecular genetics
genitogram and USS
laparascopy; biopsy
Karyotype
Work up of a patient with DSD
Hormones: Serum S 17-OH-P, Plasma-11- deoxycortisol , U-THS[Urinary tetrahydro-11- deoxycortisol].
Plasma __________ and ___________ at 1-3 month of life.
________ test to rule out Testosterone or DHT synthesis defects
Testosterone therapeutic trial: 25 mg of testosterone enanthate IM/ mo. X 3, increase > 1 cm in penis length
LH/FSH and Testosterone
HCG
In a “resourced-constrained setting” like ours
Detailed history
Careful examination with clinical picture
__________ Scan-in an experienced hand
Internal genitalia- ____________ ± _________
? Buccal smear
Hormonal studies if available ± affordable Correspondence with experts(networking)
Ultrasound
laparoscopy/laparotomy ; biopsy
Sex assignment does not always depend on karyotype.
T/F
T